Center-Authored Papers

Filters: Author is Petrylak, Daniel P  [Clear All Filters]
2009
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
2013
Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz H-J, Lee CT, Wilson SS, Benson M, Lerner SP, Tangen CM et al..  2013.  SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Non-Muscle Invasive Bladder Cancer Who Recurred Following at Least Two Prior Courses of Intravesical BCG.. The Journal of urology. Abstract
2014
Crawford DE, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger RE, Keane TE, Sieber P et al..  2014.  Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer.. Urology. Abstract
2015
Crawford DE, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A.  2015.  Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.. The Canadian journal of urology. 22(6):8048-55. Abstract
Crawford DE, Higano CS, Shore ND, Hussain M, Petrylak DP.  2015.  Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.. The Journal of urology. 194(6):1537-47. Abstract
2016
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL et al..  2016.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.. Lancet (London, England). Abstract
Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D et al..  2016.  Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M et al..  2016.  Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
2017
Crawford DE, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM et al..  2017.  The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration-Resistant Prostate Cancer (RADAR II).. Urology. Abstract
Crawford DE, Shore ND, Petrylak DP, Higano CS, Ryan CJ.  2017.  Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.. Therapeutic advances in medical oncology. 9(5):319-333. Abstract